Research ArticleArticle
Open Access
Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016
Ana-Maria Orbai, Maarten de Wit, Philip J. Mease, Kristina Callis Duffin, Musaab Elmamoun, William Tillett, Willemina Campbell, Oliver FitzGerald, Dafna D. Gladman, Niti Goel, Laure Gossec, Pil Hoejgaard, Ying Ying Leung, Chris Lindsay, Vibeke Strand, Désirée M. van der Heijde, Bev Shea, Robin Christensen, Laura Coates, Lihi Eder, Neil McHugh, Umut Kalyoncu, Ingrid Steinkoenig and Alexis Ogdie
The Journal of Rheumatology February 2017, jrheum.160904; DOI: https://doi.org/10.3899/jrheum.160904
Ana-Maria Orbai
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
Maarten de Wit
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
Philip J. Mease
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
Kristina Callis Duffin
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
Musaab Elmamoun
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
William Tillett
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
Willemina Campbell
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
Oliver FitzGerald
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
Dafna D. Gladman
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
Niti Goel
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
Laure Gossec
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
Pil Hoejgaard
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
Ying Ying Leung
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
Chris Lindsay
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
Vibeke Strand
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
Désirée M. van der Heijde
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
Bev Shea
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
Robin Christensen
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
Laura Coates
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
Lihi Eder
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
Neil McHugh
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
Umut Kalyoncu
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
Ingrid Steinkoenig
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
Alexis Ogdie
From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women’s College Research Institute, Women’s College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent’s University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women’s College Research Institute, Women’s College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: aorbai1@jhmi.edu. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016
Ana-Maria Orbai, Maarten de Wit, Philip J. Mease, Kristina Callis Duffin, Musaab Elmamoun, William Tillett, Willemina Campbell, Oliver FitzGerald, Dafna D. Gladman, Niti Goel, Laure Gossec, Pil Hoejgaard, Ying Ying Leung, Chris Lindsay, Vibeke Strand, Désirée M. van der Heijde, Bev Shea, Robin Christensen, Laura Coates, Lihi Eder, Neil McHugh, Umut Kalyoncu, Ingrid Steinkoenig, Alexis Ogdie
The Journal of Rheumatology Feb 2017, jrheum.160904; DOI: 10.3899/jrheum.160904
Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016
Ana-Maria Orbai, Maarten de Wit, Philip J. Mease, Kristina Callis Duffin, Musaab Elmamoun, William Tillett, Willemina Campbell, Oliver FitzGerald, Dafna D. Gladman, Niti Goel, Laure Gossec, Pil Hoejgaard, Ying Ying Leung, Chris Lindsay, Vibeke Strand, Désirée M. van der Heijde, Bev Shea, Robin Christensen, Laura Coates, Lihi Eder, Neil McHugh, Umut Kalyoncu, Ingrid Steinkoenig, Alexis Ogdie
The Journal of Rheumatology Feb 2017, jrheum.160904; DOI: 10.3899/jrheum.160904